Cannabis Campaigners' Guide News Database result:


After you have finished reading this article you can click here to go back.

GW Pharma's Sativex approved by New Zealand

ShareCast

Wednesday 03 Nov 2010

LONDON (SHARECAST) - Cannabis based medicines group GW Pharmaceuticals has had its Sativex treatment for the relief of spasticity in Multiple Sclerosis (MS) approved by the New Zealand regulatory authority.

The mouth spray, which contains two cannabinoids or active ingredients - THC and CBD - is the first cannabinoid medicine derived from whole plant extracts from the cannabis sativa plant.

It's the fourth approval for Sativex in recent months following positive decisions in the UK, Spain and Canada.

"We are delighted that Sativex has received positive endorsement from another of the world's most highly regarded regulatory authorities," GW R&D director Stephen Wright said.

http://www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=3798085

 

 

 

After you have finished reading this article you can click here to go back. 




This page was created by the Cannabis Campaigners' Guide.

Feel free to link to this page!